



International  
Federation of  
Pharmaceutical  
Manufacturers &  
Associations

Fédération  
Internationale de  
l'Industrie du  
Médicament

Federación  
Internacional de la  
Industria del  
Medicamento



## News Release

### **IFPMA President Calls on Research-Based Pharmaceutical Industry to Continue its MDG Contributions Beyond 2015**

Geneva, 16 September 2010 – The United Nations Summit on the Millennium Development Goals on 20-22 September will review progress and look at ways of accelerating progress. The UN's 2010 MDG Report indicates that the goals are achievable, despite uneven progress, and exhorts everyone to try to keep the promise of the Millennium Declaration.

Mr. Haruo Naito, President of the IFPMA and President & CEO of Eisai Co., Ltd., said: "The research-based pharmaceutical industry shares the UN Secretary General's belief in the importance of the MDGs for humankind and has responded with a broad range of contributions, mostly aimed at improving health in developing countries. While achievement of the MDGs will help to put us on the path towards a more stable, just and secure world, they will only take us so far in that direction. A longer-term effort is needed to further reduce global health inequalities, and I therefore encourage our industry to maintain its MDG-related efforts beyond the 2015 horizon. The research-based pharmaceutical industry plays a unique role in improving health: we cannot fix health inequalities on our own, but we need to keep playing our part."

The research-based pharmaceutical industry's main contribution to improved global health lies in its unique role in developing new medicines and vaccines for all diseases. In addition, it helps to work towards achievement of the health-related UN MDGs through a large and growing range of programs, working with expert partner organizations from both public and private sectors to improve health in developing countries. These partnerships facilitate access to medicines, strengthen healthcare systems, educate patients and populations at risk, and conduct research and development to create new medicines and vaccines to address diseases which disproportionately affect developing countries.<sup>1</sup>

**(Ends)**

<sup>1</sup> For details, see Note to the Editor "Overview of Research-Based Pharmaceutical Industry Contributions to the Health-Related UN MDGs" IFPMA, 16 September 2010

**About the IFPMA:**

The International Federation of Pharmaceutical Manufacturers & Associations is the global non-profit NGO representing the research-based pharmaceutical industry, including the biotech and vaccine sectors. Its members comprise 25 leading international companies and 46 national and regional industry associations covering developed and developing countries. The industry's R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, heart disease, HIV/AIDS and malaria. The IFPMA Clinical Trials Portal ([www.ifpma.org/ClinicalTrials](http://www.ifpma.org/ClinicalTrials)), the IFPMA's Ethical Promotion online resource ([www.ifpma.org/EthicalPromotion/](http://www.ifpma.org/EthicalPromotion/)) and its Developing World Health Partnerships Directory ([www.ifpma.org/HealthPartnerships](http://www.ifpma.org/HealthPartnerships)) help make the industry's activities more transparent. The IFPMA supports a wide range of WHO technical activities, notably those relating to medicine efficacy, quality and safety, and coordinates industry participation in the WHO IMPACT initiative to combat counterfeit medicines. It also provides the secretariat for the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

**For further information, please contact:**

Guy Willis  
Director of Communications  
E-mail: [g.willis@ifpma.org](mailto:g.willis@ifpma.org)  
Tel: +41 22 338 32 00  
Fax: +41 22 338 32 99  
Web: [www.ifpma.org](http://www.ifpma.org)